PapersFlow Research Brief
Vasculitis and related conditions
Research Guide
What is Vasculitis and related conditions?
Vasculitis and related conditions refer to a cluster of inflammatory diseases affecting blood vessels, including ANCA-associated vasculitis, giant cell arteritis, polyarteritis nodosa, Churg-Strauss syndrome, and Takayasu arteritis, with established nomenclature, diagnostic criteria, and management strategies such as rituximab therapy.
The field encompasses 70,179 published works on the classification, diagnosis, and management of vasculitides. Jennette et al. (2012) in "2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides" updated the nomenclature for systemic vasculitides, building on prior consensus efforts. EULAR recommendations guide rituximab use and imaging for monitoring, as highlighted in the topic description.
Topic Hierarchy
Research Sub-Topics
ANCA-Associated Vasculitis
This sub-topic covers diagnosis, pathogenesis, and treatment of GPA, MPA, and EGPA, emphasizing ANCA roles and rituximab efficacy. Researchers conduct trials on relapse prevention and biomarkers.
Giant Cell Arteritis
Focuses on clinical features, glucocorticoid tapering, and biologics like tocilizumab for cranial and extracranial GCA. Studies explore imaging diagnostics and long-term outcomes.
Takayasu Arteritis
Investigates vascular inflammation, stenosis progression, and immunosuppressive therapies in young patients. Research includes MRI monitoring and genetic risk factors.
Polyarteritis Nodosa
This area examines classic and cutaneous PAN, HBV associations, and cyclophosphamide/glucocorticoid regimens. Studies differentiate from mimics and assess aneurysms.
Rituximab in Vasculitis
Researchers evaluate rituximab's role in induction, maintenance, and refractory vasculitis via RCTs and real-world data. Focus includes B-cell depletion and infection risks.
Why It Matters
Vasculitis management impacts patients with severe organ-threatening disease, where therapies like rituximab achieve remission rates comparable to cyclophosphamide. Stone et al. (2010) in "Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis" demonstrated rituximab was not inferior for inducing remission in severe ANCA-associated vasculitis (New England Journal of Medicine), with potential superiority in relapsing cases among 197 patients. Classification criteria from Hunder et al. (1990) in "The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis" enable 93.5% sensitivity and 91.2% specificity for giant cell arteritis diagnosis, aiding timely glucocorticoid initiation to prevent vision loss. These standards support clinical trials and personalized treatment in rheumatology and nephrology.
Reading Guide
Where to Start
"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides" by Jennette et al. (2012) provides the foundational updated definitions and categories essential for understanding all subsequent classification and diagnostic papers.
Key Papers Explained
Jennette et al. (1994) in "Nomenclature of Systemic Vasculitides" established initial Chapel Hill definitions, refined by Jennette et al. (2012) in "2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides" to incorporate new evidence. Hunder et al. (1990), Arend et al. (1990), and Masi et al. (1990) applied these to ACR criteria for giant cell arteritis, Takayasu arteritis, and Churg-Strauss syndrome, respectively, enabling specific classifications. Stone et al. (2010) in "Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis" then demonstrated therapeutic advances building on diagnostic foundations.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Consensus nomenclature from Jennette et al. (2012) guides ongoing refinements in EULAR recommendations for rituximab and imaging, as per topic description. Focus shifts to relapse prevention in ANCA-associated cases post-Stone et al. (2010). No recent preprints or news available, so frontiers emphasize applying criteria to emerging multimodal imaging for monitoring.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | 2012 Revised International Chapel Hill Consensus Conference No... | 2012 | Arthritis & Rheumatism | 6.4K | ✓ |
| 2 | Standardization of Uveitis Nomenclature for Reporting Clinical... | 2005 | American Journal of Op... | 4.2K | ✓ |
| 3 | Nomenclature of Systemic Vasculitides | 1994 | Arthritis & Rheumatism | 3.8K | ✕ |
| 4 | Criteria for diagnosis of Behçet's disease | 1990 | The Lancet | 3.1K | ✕ |
| 5 | The Banff 97 working classification of renal allograft pathology | 1999 | Kidney International | 3.0K | ✕ |
| 6 | Wegener Granulomatosis: An Analysis of 158 Patients | 1992 | Annals of Internal Med... | 2.9K | ✕ |
| 7 | Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis | 2010 | New England Journal of... | 2.7K | ✓ |
| 8 | The American College of Rheumatology 1990 criteria for the cla... | 1990 | Arthritis & Rheumatism | 2.5K | ✕ |
| 9 | The American College of Rheumatology 1990 criteria for the cla... | 1990 | Arthritis & Rheumatism | 2.2K | ✕ |
| 10 | The American College of Rheumatology 1990 criteria for the cla... | 1990 | Arthritis & Rheumatism | 2.2K | ✕ |
Frequently Asked Questions
What is the Chapel Hill Consensus nomenclature for vasculitides?
The "2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides" by Jennette et al. (2012) provides updated names and definitions for vasculitides, distinguishing large, medium, and small vessel involvement. It refines categories like ANCA-associated vasculitis and giant cell arteritis. This nomenclature aids uniform reporting in research and practice.
How does rituximab compare to cyclophosphamide in ANCA-associated vasculitis?
Stone et al. (2010) in "Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis" showed rituximab was not inferior to daily cyclophosphamide for remission induction in severe cases. Rituximab may excel in relapsing disease. The trial involved funding from the National Institutes of Allergy and Infectious Diseases.
What are the ACR criteria for giant cell arteritis?
Hunder et al. (1990) in "The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis" selected five criteria: age ≥50 years, new headache, temporal artery abnormality, elevated ESR, and positive artery biopsy. These yield high sensitivity and specificity for classification. They were developed from 214 patients versus 593 controls.
What defines Takayasu arteritis per ACR criteria?
Arend et al. (1990) in "The American College of Rheumatology 1990 criteria for the classification of takayasu arteritis" include six criteria: onset ≤40 years, claudication, decreased brachial pulse, blood pressure difference >10 mmHg, bruit, and arteriogram abnormality. Classification requires ≥3 criteria from 63 patients versus 744 controls. These facilitate early diagnosis.
What are the diagnostic criteria for Churg-Strauss syndrome?
Masi et al. (1990) in "The American College of Rheumatology 1990 criteria for the classification of churg‐strauss syndrome (allergic granulomatosis and angiitis)" list six: asthma, eosinophilia >10%, neuropathy, pulmonary infiltrates, paranasal sinus abnormality, and extravascular eosinophils. Four or more criteria classify the disease from 20 patients versus 787 controls. This supports differentiation from other vasculitides.
What role did cyclophosphamide play in Wegener granulomatosis?
Hoffman et al. (1992) in "Wegener Granulomatosis: An Analysis of 158 Patients" reported daily cyclophosphamide with glucocorticoids improved outcomes dramatically in 158 patients. Remission rates were high, though morbidity persisted. Alternative therapies were explored for better tolerability.
Open Research Questions
- ? How can imaging modalities be optimized for early detection and monitoring of vasculitis activity across vessel sizes?
- ? What predictors identify patients at highest risk for relapse in ANCA-associated vasculitis post-remission?
- ? Which refinements to classification criteria improve diagnostic accuracy for overlapping vasculitides like Takayasu arteritis and giant cell arteritis?
- ? How do long-term outcomes differ between rituximab maintenance and cyclophosphamide in preventing organ damage?
- ? What biomarkers distinguish active vasculitis from treatment-related damage in renal and pulmonary manifestations?
Recent Trends
The field maintains 70,179 works with no specified 5-year growth rate.
Core advancements stem from 2012 nomenclature by Jennette et al. and 2010 rituximab trial by Stone et al., with no new preprints or news in the last 12 months.
Established criteria from 1990 ACR papers by Hunder, Arend, and Masi et al. continue to underpin diagnosis.
Research Vasculitis and related conditions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Vasculitis and related conditions with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers